USA flag logo/image

An Official Website of the United States Government

Targeting drug delivery nanoparticles to sites of inflammation

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
80348
Program Year/Program:
2008 / STTR
Agency Tracking Number:
EY017518
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
POTENTIA PHARMACEUTICALS, INC
POTENTIA PHARMACEUTICALS, INC 201 E JEFFERSON ST, STE 312 LOUISVILLE, KY 40202
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2008
Title: Targeting drug delivery nanoparticles to sites of inflammation
Agency: HHS
Contract: 2R42EY017518-02
Award Amount: $977,329.00
 

Abstract:

DESCRIPTION (provided by applicant): The purpose of this Phase II STTR project is to develop a nanoparticle-based drug delivery system for use in the treatment of dry age-related macular degeneration (AMD). AMD is the leading cause of blindness for individ uals over fifty-five years of age that live in the industrialized world, affecting approximately 10 million people in the US and as many as 30 million worldwide. There are two forms of the disease, both of which cause a loss of central vision. Approximatel y fifteen percent have wet, or exudative, AMD, which causes rapid, disabling blindness. The remaining eighty-five percent of patients have dry AMD, a less severe form that produces gradual vision loss. At present, there are no approved pharmacological agen ts approved for the treatment of dry AMD. This project seeks study to develop a smart poly-lactic, glycolic acid (PLGA) nanoparticle drug delivery system that can home to sites of inflammation after intravenous injection. Homing is achieved through a mec hanism similar to one used by lymphocytes recognize regions of inflammation. Once there, the particles will release a complement inhibitor over a sustained period time. A growing body of research links excessive complement activation with several diseases of aging, including AMD. The prototype nanoparticle developed in Phase I is able to selectively bind activated endothelial cells in cell culture. In vivo studies further show that the nanoparticles are able to bind inflamed blood vessels in the eye. In vit ro studies showed that they are also able to release a complement inhibitor for periods in excess of 60 days. PUBLIC HEALTH RELEVANCE This application is critically concerned with developing a drug product that can be used to treat nonexudative age-related macular degeneration. There are currently no approved treatments for this disorder, making it a major the issue of public health. In the longer term, the goal of this work is to develop drug products that can selectively target and treat sites of disease action, particularly those associated inflammation and degenerative disease.

Principal Investigator:

Business Contact:


pascal@potentiapharma.com
Small Business Information at Submission:

POTENTIA PHARMACEUTICALS, INC
POTENTIA PHARMACEUTICALS, INC 201 E JEFFERSON ST, STE 312 LOUISVILLE, KY 40202

EIN/Tax ID: 043575012
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No